QR Pharma’s Posiphen Was Shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein

Published: Jul 14, 2010

RADNOR, Pa.--(BUSINESS WIRE)--QR Pharma, Inc., a developer of novel drugs to treat Alzheimer’s disease (AD), is presenting a poster today on positive clinical data from its recent mechanism of action study in mild cognitive impaired (MCI) patients at the International Congress on Alzheimer’s Disease (ICAD 2010).

Back to news